SequelSEC

TriSalus Life Sciences, Inc. TLSI

Surgical & Medical Instruments & Apparatus · CIK 0001826667 · Fiscal year ends 1231

AnnualQuarterlyTTM
Revenue
$45.08M
Fiscal year ended 2026-06-30
Operating income
-$30.51M
Fiscal year ended 2026-06-30
Free cash flow
-$23.28M
Fiscal year ended 2026-06-30

Valuation, from the filing

Public float$111.50MMarket value of stock held by non-affiliates, as stated on the cover page for 2025-06-30
Float per share$1.82Float divided by shares outstanding in the same filing. A floor under the share price on that date, not the price itself.
Float / revenue2.5×A lower bound on the multiple, because affiliate holdings are excluded.

Every figure here is drawn from the 10-K cover page and the statements behind it, so each one traces to a filing. Public float counts only stock held by non-affiliates, which makes these floors rather than estimates: a high multiple is conclusive, a low one may mean cheap or may mean closely held. The float was measured on 2025-06-30, not today, and each multiple below it uses the figures for the fiscal year ending 2025-12-31 — the year that filing covered.

How this compares in its industry

Percentile among the Surgical & Medical Instruments & Apparatus filers on this site, highest value first. A high percentile means a large figure, which is good for a margin and not for leverage — the ranking says where the company sits, not whether that is where it should be.

MeasureReportedPercentile
Gross margin84.6%92th
Revenue YoY growth53.4%85th
SBC / revenue20.2%75th
Net margin-86.9%28th
Operating margin-59.7%33th
R&D / revenue33.1%66th
FCF margin-41.9%34th
CapEx / revenue2.0%42th
Current ratio2.80x50th

TriSalus Life Sciences, Inc. (TLSI) reported revenue of $45.08M and net income of -$28.21M for the fiscal year ended 2026-06-30. This page shows 1 annual period of income statement, balance sheet and cash flow figures normalized from TriSalus Life Sciences, Inc.’s SEC filings, each linked to the filing it came from. It is classified by the SEC under Surgical & Medical Instruments & Apparatus.

Income

TriSalus Life Sciences, Inc. income by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Revenue$45.08M
Cost of revenue$6.41M
Gross profit$38.67M
Operating income-$30.51M
Net income-$28.21M
Research & development$14.10M
Weighted-average diluted sharesUnavailable
Pretax income-$28.20M
Income tax expense$13.00K
Diluted EPSUnavailable
Selling, general & administrative$55.08M
General & administrative$21.44M
Selling & marketing$33.64M

Balance

TriSalus Life Sciences, Inc. balance by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Cash & equivalents$46.29M
Total assets$62.45M
Current assets$59.74M
Total liabilities$55.90M
Current liabilities$11.17M
Total equity incl. NCI$6.55M
Temporary (mezzanine) equityUnavailable
Inventory$4.20M
Accounts receivable$6.46M
GoodwillUnavailable
Long-term debt$33.06M
Accounts payableUnavailable

Cash flow

TriSalus Life Sciences, Inc. cash flow by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Operating cash flow-$22.80M
Capital expenditures$480.00K
Investing cash flow-$440.00K
Financing cash flow$42.69M
Net change in cash$19.45M
Stock-based compensation$10.71M
Common dividends paidUnavailable
Common share repurchasesUnavailable
Depreciation & amortization$560.00K

Derived

TriSalus Life Sciences, Inc. derived by fiscal year, in US dollars, normalized from SEC filings.
Metric2026-06-30
Free cash flow-$23.28M
Gross margin85.8%
Operating margin-67.7%
FCF margin-51.6%
SBC / revenue23.8%
Current ratio5.35x
Revenue YoY growth25.2%
Net margin-62.6%
R&D / revenue31.3%
CapEx / revenue1.1%
Long-term debt / equity5.05x
Effective tax rateUnavailable

Amounts are abbreviated; the exact reported value is carried in each cell. — means unavailable, not zero. Open TLSI in the interactive workspace to inspect any figure back to its filing.

Source filings

10-Q · Filed 2026-08-06View SEC filing
10-Q · Filed 2026-05-12View SEC filing
10-K · Filed 2026-03-05View SEC filing
10-Q · Filed 2025-11-13View SEC filing
10-Q · Filed 2025-08-12View SEC filing
10-K/A · Filed 2025-05-30View SEC filing

Companies in the same industry

ADGM AEMD ALUR AMIX ANGO ANIK AORT APYX ARAY ATEC ATRC AURX

Every accounting identity this site checks — the balance sheet, the gross profit bridge and the cash flow statement — reconciles in every period shown.